Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sets New 1-Year High on Analyst Upgrade
Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s share price hit a new 52-week high on Tuesday after Jefferies Group upgraded the stock from a hold rating to a buy rating. Jefferies Group now has a $55.00 price target on the stock. Esperion Therapeutics traded as high as $56.44 and last traded at $56.81, with a volume of 2,826,725 shares changing hands. The stock had previously closed at $45.17.
Other equities analysts have also recently issued research reports about the company. BidaskClub cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. UBS AG restated a “buy” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Stifel Nicolaus restated a “buy” rating and issued a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. Deutsche Bank AG initiated coverage on Esperion Therapeutics in a report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective for the company. Finally, Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $40.39.
A number of large investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $158,000. C WorldWide Group Holding A S purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $162,000. Princeton Alpha Management LP purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $205,000. Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the period. Finally, Aperio Group LLC purchased a new stake in shares of Esperion Therapeutics during the second quarter valued at about $249,000. Institutional investors and hedge funds own 85.20% of the company’s stock.
The stock’s 50 day moving average is $44.47 and its 200 day moving average is $33.65. The stock’s market capitalization is $1.14 billion.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same period last year, the company earned ($0.62) EPS. Analysts predict that Esperion Therapeutics, Inc. will post ($7.18) earnings per share for the current fiscal year.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.